May 6th 2024
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
FDA Grants Priority Review to sBLA for Adjuvant Pembrolizumab in RCC
August 10th 2021The FDA has accepted a supplemental biologics license application for adjuvant pembrolizumab and granted it priority review as a treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Read More
Updated Findings Support Pembrolizumab/Lenvatinib as a Standout Option for Frontline RCC Treatment
July 24th 2021In an interview, Robert J. Motzer, MD, explained how further results of the CLEAR trial, including health-related QOL data, suggest the benefit of pembrolizumab and lenvatinib in patients with advanced RCC.
Read More
Overall Survival Results of I/O Combinations Differ Across Risk Groups of Metastatic RCC
July 22nd 2021The overall survival benefit of immunotherapy combinations compared with sunitinib for the treatment of patients with metastatic renal cell carcinoma who have favorable risk may differ from those who have intermediate or poor risk, according to a pooled analysis of frontline combination therapy conducted by the FDA.
Read More
ARO-HIF2 Shows Signals of Activity, Safety in Clear Cell Renal Cell Carcinoma
July 8th 2021ARO-HIF2, an investigational tumor-targeting medicine utilizing the Targeted RNAi molecule platform from Arrowhead Pharmaceuticals, Inc., may be a safe and effective treatment for patients with clear cell renal cell carcinoma.
Read More
Follow-Up Shows Continued Efficacy in RCC With Pembrolizumab/Axitinib
July 7th 2021Brian I. Rini, MD, discusses the benefits of long-term follow-up for trials and the results from 42-month follow-up of the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line therapy for patients with advanced clear cell renal cell carcinoma.
Watch
Lenvatinib/Pembrolizumab Combo Shows Promising Antitumor Activity in mRCC
June 25th 2021Pembrolizumab plus lenvatinib demonstrated antitumor activity and a manageable safety profile in patients with metastatic renal cell carcinoma who have previously received immune checkpoint inhibitor therapy.
Read More
Belzutifan Shows Strong Responses in RCC and Other VHL-Associated Lesions
June 9th 2021Updated findings for belzutifan showed that with further follow-up, the hypoxia-inducible factor-2 alpha inhibitor continues to show significant clinical activity in patients with Von-Hippel Lindau–associated renal cell carcinoma treated in the frontline setting. Updated results from the phase 2 study.
Read More
Pembrolizumab Plus Cabozantinib Achieves High Response Rate in Metastatic RCC
June 9th 2021More the half of patients with metastatic renal cell carcinoma who received pembrolizumab in combination with cabozantinib had a response to the combination at the recommended phase 2 dose and tolerated treatment well.
Read More
Efficacy Improved with Lenvatinib/Pembrolizumab Combo Over Sunitinib Across RCC Risk Groups
June 9th 2021Efficacy was improved with Lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups over sunitinib.
Read More
Pembrolizumab/Lenvatinib Combo Supported by HRQOL Analysis From CLEAR Trial in Frontline RCC
June 7th 2021Similar health-reatled quality of life outcomes and disease-related symptom scores were seen between the combination of lenvatinib plus pembrolizumab and sunitinib for the frontline treatment of metastatic renal cell carcinoma.
Read More
Adjuvant Pembrolizumab Significantly Reduces Risk of Disease Recurrence or Death in RCC
June 3rd 2021Data from the phase 3 KEYNOTE-564 trial presented in a press briefing ahead of the 2021 ASCO Annual Meeting showed that adjuvant pembrolizuumab achieved significant disease-free survival improvement compared with placebo.
Read More
Lenvatinib/Everolimus Shows Potential as Second-Line Therapy After CheckMate 9ER Regimen in RCC
May 29th 2021The CheckMate 9ER study compared nivolumab plus cabozantinib with sunitinib and found that as disease becomes less favorable by prognostic risk. Promise has now been shown for this population with the combination of lenvatinib and everolimus.
Read More
Cabozantinib Shows Potential for Treating Papillary RCC Population
May 11th 2021Sumanta Kumar Pal, MD, a medical oncologist at the City of Hope Cancer Center, discussed the SWOG 1500 trial, the potential of cabozantinib for the treatment of papillary RCC, and the future of RCC care in an interview with Targeted Oncology,
Read More